NeurologyLive® Friday 5 — February 14, 2024

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Addressing Social Isolation in Narcolepsy and Idiopathic Hypersomnia: Julie Flygare, JD

The president and CEO at Project Sleep highlighted the need for clinicians to facilitate awareness of patient advocacy resources for those living with narcolepsy or idiopathic hypersomnia. [WATCH TIME: 5 minutes]

2: Safety Considerations and Personalizing SPN-830 Treatment for Parkinson Disease: Stuart Isaacson, MD, FAAN

The director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton, Florida, commented on the promising safety of SPN-830 and who may be best suited for treatment with the newly approved therapy. [WATCH TIME: 4 minutes]

3: Expanding the Time Window for Intravenous Thrombolysis in Ischemic Stroke: Min Lou MD, PhD

The professor at the Second Affiliated Hospital of Zhejiang University’s School of Medicine discussed findings from a trial suggesting that intravenous thrombolysis could benefit patients with ischemic stroke up to 24 hours after symptom onset. [WATCH TIME: 8 minutes]

4: NeuroVoices: Véronique Miron, PhD, on Exciting Developments and Expectations for ACTRIMS 2025

The John David Eaton Chair in Multiple Sclerosis at the University of Toronto gave an overview for the upcoming ACTRIMS Forum, highlighting key sessions, themes, and advances in the multiple sclerosis field.

5: Advancing Clinical Trials and Treatment Strategies for Charcot-Marie-Tooth Disease: Joshua Burns, PhD

The clinical researcher at St. Jude Children's Research Hospital discussed the evolving treatment landscape for Charcot-Marie-Tooth disease, which will be featured in a session at the 2025 MDA Conference. [WATCH TIME: 7 minutes]